566 related articles for article (PubMed ID: 15940266)
21. Two-step colocalization of MORC3 with PML nuclear bodies.
Mimura Y; Takahashi K; Kawata K; Akazawa T; Inoue N
J Cell Sci; 2010 Jun; 123(Pt 12):2014-24. PubMed ID: 20501696
[TBL] [Abstract][Full Text] [Related]
22. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
23. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia.
Boddy MN; Howe K; Etkin LD; Solomon E; Freemont PS
Oncogene; 1996 Sep; 13(5):971-82. PubMed ID: 8806687
[TBL] [Abstract][Full Text] [Related]
24. SUMO-1 promotes association of SNURF (RNF4) with PML nuclear bodies.
Häkli M; Karvonen U; Jänne OA; Palvimo JJ
Exp Cell Res; 2005 Mar; 304(1):224-33. PubMed ID: 15707587
[TBL] [Abstract][Full Text] [Related]
25. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; de Thé H; Hay RT; Freemont PS
J Cell Sci; 1999 Feb; 112 ( Pt 3)():381-93. PubMed ID: 9885291
[TBL] [Abstract][Full Text] [Related]
26. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
27. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
28. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.
Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M
Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858
[TBL] [Abstract][Full Text] [Related]
29. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
30. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
Engelhardt OG; Ullrich E; Kochs G; Haller O
Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
[TBL] [Abstract][Full Text] [Related]
31. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
32. [Research advances on function of promyelocytic leukemia (PML) protein].
He PC; Zhang M; Wang F
Ai Zheng; 2003 Dec; 22(12):1359-62. PubMed ID: 14693070
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
[TBL] [Abstract][Full Text] [Related]
34. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation.
Cho G; Lim Y; Golden JA
J Biol Chem; 2009 Jul; 284(29):19592-600. PubMed ID: 19416967
[TBL] [Abstract][Full Text] [Related]
35. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein.
Kang H; Kim ET; Lee HR; Park JJ; Go YY; Choi CY; Ahn JH
J Gen Virol; 2006 Aug; 87(Pt 8):2181-2190. PubMed ID: 16847114
[TBL] [Abstract][Full Text] [Related]
37. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
38. PML positively regulates interferon gamma signaling.
El Bougrini J; Dianoux L; Chelbi-Alix MK
Biochimie; 2011 Mar; 93(3):389-98. PubMed ID: 21115099
[TBL] [Abstract][Full Text] [Related]
39. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
40. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein.
Takahashi H; Hatakeyama S; Saitoh H; Nakayama KI
J Biol Chem; 2005 Feb; 280(7):5611-21. PubMed ID: 15569683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
